Enovis [ENOV] vs QuidelOrtho [QDEL] Detailed Stock Comparison
Enovis
NYSE
Loading...
QuidelOrtho
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Enovis wins in 6 metrics, QuidelOrtho wins in 12 metrics, with 0 ties. QuidelOrtho appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Enovis | QuidelOrtho | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.91 | -0.78 | Enovis |
| Price-to-Book Ratio | 0.62 | 0.53 | QuidelOrtho |
| Debt-to-Equity Ratio | 55.68 | 90.01 | Enovis |
| PEG Ratio | 9.03 | 8.95 | QuidelOrtho |
| EV/EBITDA | 8.95 | 7.49 | QuidelOrtho |
| Profit Margin (TTM) | -37.65% | -12.97% | QuidelOrtho |
| Operating Margin (TTM) | -5.50% | 7.03% | QuidelOrtho |
| EBITDA Margin (TTM) | N/A | 7.03% | N/A |
| Return on Equity | -27.35% | -11.38% | QuidelOrtho |
| Return on Assets (TTM) | 0.49% | 1.12% | QuidelOrtho |
| Free Cash Flow (TTM) | $-67.21M | $-112.10M | Enovis |
| 1-Year Return | -34.47% | -42.55% | Enovis |
| Price-to-Sales Ratio (TTM) | 0.76 | 0.58 | QuidelOrtho |
| Enterprise Value | $2.89B | $4.20B | QuidelOrtho |
| EV/Revenue Ratio | 1.35 | 1.52 | Enovis |
| Gross Profit Margin (TTM) | 59.45% | 49.55% | Enovis |
| Revenue per Share (TTM) | $39 | $41 | QuidelOrtho |
| Earnings per Share (Diluted) | $-14.64 | $-5.23 | QuidelOrtho |
| Beta (Stock Volatility) | 1.81 | -0.03 | QuidelOrtho |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Enovis vs QuidelOrtho Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Enovis | -0.28% | 10.49% | -18.13% | -14.03% | -36.06% | -35.80% |
| QuidelOrtho | -2.01% | 4.82% | -22.42% | -34.42% | -44.25% | -46.91% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Enovis | -34.47% | -52.47% | -52.16% | -58.10% | 33.33% | -19.39% |
| QuidelOrtho | -42.55% | -71.57% | -90.28% | 13.75% | 97.11% | 233.94% |
Performance & Financial Health Analysis: Enovis vs QuidelOrtho
| Metric | ENOV | QDEL |
|---|---|---|
| Market Information | ||
| Market Cap | $1.63B | $1.60B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,338,293 | 1,435,853 |
| 90 Day Avg. Volume | 1,718,024 | 1,682,134 |
| Last Close | $28.44 | $23.91 |
| 52 Week Range | $25.47 - $49.83 | $22.05 - $49.45 |
| % from 52W High | -42.93% | -51.65% |
| All-Time High | $129.72 (Jun 09, 2014) | $306.72 (Aug 03, 2020) |
| % from All-Time High | -78.08% | -92.20% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | -0.03% |
| Quarterly Earnings Growth | 0.08% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | -0.38% | -0.13% |
| Operating Margin (TTM) | -0.06% | 0.07% |
| Return on Equity (TTM) | -0.27% | -0.11% |
| Debt to Equity (MRQ) | 55.68 | 90.01 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $45.83 | $44.40 |
| Cash per Share (MRQ) | $0.67 | $1.89 |
| Operating Cash Flow (TTM) | $148.06M | $149.30M |
| Levered Free Cash Flow (TTM) | $-63,732,752 | $297.44M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Enovis vs QuidelOrtho
| Metric | ENOV | QDEL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.91 | -0.78 |
| Forward P/E | 9.03 | 8.95 |
| PEG Ratio | 9.03 | 8.95 |
| Price to Sales (TTM) | 0.76 | 0.58 |
| Price to Book (MRQ) | 0.62 | 0.53 |
| Market Capitalization | ||
| Market Capitalization | $1.63B | $1.60B |
| Enterprise Value | $2.89B | $4.20B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.35 | 1.52 |
| Enterprise to EBITDA | 8.95 | 7.49 |
| Risk & Other Metrics | ||
| Beta | 1.81 | -0.03 |
| Book Value per Share (MRQ) | $45.83 | $44.40 |
Financial Statements Comparison: Enovis vs QuidelOrtho
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ENOV | QDEL |
|---|---|---|
| Revenue/Sales | $558.83M | $692.80M |
| Cost of Goods Sold | $226.61M | $349.50M |
| Gross Profit | $332.23M | $343.30M |
| Research & Development | $28.53M | $53.20M |
| Operating Income (EBIT) | $-42.91M | $48.70M |
| EBITDA | $27.14M | $154.20M |
| Pre-Tax Income | $-57.35M | $-8.80M |
| Income Tax | $-1.77M | $3.90M |
| Net Income (Profit) | $-55.71M | $-12.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ENOV | QDEL |
|---|---|---|
| Cash & Equivalents | $38.46M | $127.10M |
| Total Current Assets | $1.22B | $1.26B |
| Total Current Liabilities | $477.42M | $1.05B |
| Long-Term Debt | $1.42B | $2.27B |
| Total Shareholders Equity | $2.62B | $3.00B |
| Retained Earnings | $-338.99M | $123.10M |
| Property, Plant & Equipment | $492.24M | $2.35B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ENOV | QDEL |
|---|---|---|
| Operating Cash Flow | $-1.07M | $41.90M |
| Capital Expenditures | $-43.26M | $-56.20M |
| Free Cash Flow | $-44.86M | $9.40M |
| Debt Repayment | $-15.44M | $-36.00M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ENOV | QDEL |
|---|---|---|
| Shares Short | 7.43M | 6.25M |
| Short Ratio | 4.68 | 3.68 |
| Short % of Float | 0.20% | 0.15% |
| Average Daily Volume (10 Day) | 1,338,293 | 1,435,853 |
| Average Daily Volume (90 Day) | 1,718,024 | 1,682,134 |
| Shares Outstanding | 55.88M | 67.26M |
| Float Shares | 56.40M | 62.35M |
| % Held by Insiders | 0.02% | 0.01% |
| % Held by Institutions | 1.07% | 1.15% |
Dividend Analysis & Yield Comparison: Enovis vs QuidelOrtho
| Metric | ENOV | QDEL |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | $0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |